SelectScience InterviewsDrug Discovery & Development
An in vivo safety and efficacy model for T-cell engagers
11 Sept 2024
Cameron Smith-Craig
Pharma and Applied Sciences Editor
Dr. Vincent Muczynski, Research Associate at University College London, presents an in vivo safety and efficacy model for T-cell engagers using adeno-associated virus (AAV) vectors. Explore some of the humanized mouse models available to determine toxicity and efficacy on the path to the clinic.
This video was filmed in partnership with The Jackson Laboratory.
About the company
The Jackson Laboratory
The Jackson Laboratory is a global leader in preclinical studies and has been driving therapeutic development breakthroughs for over 90 years. With the most innovative preclinical platforms including humanized mice, and services such as dose ranging, toxicity, and efficacy studies, JAX empowers drug developers and researchers worldwide.
Other videos from The Jackson Laboratory
Links
Tags
Animal ModelsThe use of non-human animals in experiments or behavorial observations. The research is conducted inside universities, medical schools, pharmaceutical companies, farms, defence establishments, and commercial facilities that provide animal-testing services to industry. It includes pure research such as genetics, developmental biology, behavioral studies, as well as applied research such as pharmaceutical testing in pre-clinical, before human, studies. CAR-T cell therapyT Cells